Resumo

ECHEZURIA M, Franklin E  e  QUIJADA M, Rosanna J. Citicolina, devemos continuar a indicá-lo nA DCbV isquemica?. Med. crít. (Col. Mex. Med. Crít.) [online]. 2018, vol.32, n.4, pp.232-236.  Epub 30-Jun-2020. ISSN 2448-8909.

Ischemic cerebrovascular disease (CVD) is a medical condition that, according to its extension, implies significant disability for the patient, as well as high costs for its acute and chronic treatment, as well in the management of disability, with high incidence and worldwide prevalence, from the physiopathological point of view represents a catastrophe in brain functioning that involves structural and functional damage. Multiple strategies have been developed for the management of this pathology, currently the gold standard for its management is the rt-PA, however, due to its characteristics, and few patients have access to it, because it various pharmacological strategies have been developed. Citicoline has been used for years, nevertheless generates controversies since its usefulness, demonstrated in experimental studies, has not been reproduced in clinical practice but some studies suggest that it could worsen the patient’s prognosis, which would justify the abandonment of its use in the treatment of ischemic CVD (ictus), for this reason we offer this review of the subject in order to provide tools to clarify this controversy.

Palavras-chave : Ischemic cerebrovascular disease; ictus; citicoline; neuroprotection.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )